Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.
The first data emerge from the circulating cancer genome atlas trial.
In a truly extraordinary year, the top 10 venture rounds made up more than half of the total invested.
Vast amounts of venture cash are available to medical device makers, but its distribution is uneven.
So far, 2017 has been a record-breaker in a number of ways – and none of them bode well for start-ups.